Aquatic Capital Management LLC Boosts Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Aquatic Capital Management LLC grew its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 3,486.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 89,655 shares of the biopharmaceutical company’s stock after purchasing an additional 87,155 shares during the period. Aquatic Capital Management LLC owned approximately 0.07% of Dynavax Technologies worth $1,145,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Russell Investments Group Ltd. increased its stake in Dynavax Technologies by 96.5% in the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 1,169 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 2,034 shares in the last quarter. GAMMA Investing LLC lifted its position in Dynavax Technologies by 55.1% during the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 1,457 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in Dynavax Technologies in the 4th quarter worth approximately $71,000. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Dynavax Technologies by 19.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 1,076 shares during the last quarter. Institutional investors own 96.96% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. HC Wainwright reissued a “buy” rating and set a $31.00 price objective on shares of Dynavax Technologies in a report on Friday, February 21st. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, February 24th. Finally, The Goldman Sachs Group lowered their price objective on shares of Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating for the company in a report on Thursday, April 17th.

Dynavax Technologies Stock Performance

Shares of DVAX stock opened at $11.55 on Wednesday. The company has a market capitalization of $1.41 billion, a P/E ratio of 64.17 and a beta of 1.26. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $14.63. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The stock has a 50 day moving average price of $12.70 and a two-hundred day moving average price of $12.58.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting analysts’ consensus estimates of $0.05. The company had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. Analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.